Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 251 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Lymphoma
Interventions
darbepoetin alfa, filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Leukemia
Interventions
Lenalidomide, Darbepoetin alfa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anemia
Interventions
Erythropoietin alpha, Placebo
Drug
Lead sponsor
Mathew S. Maurer
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Optimized Erythropoietin (EPO) Treatment

NCT02075970
Conditions
Neonatal Anemia
Interventions
Epoetin Alpha
Drug
Lead sponsor
University of Iowa
Other
Eligibility
Up to 2 Days
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Anaemia
Interventions
Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas
Conditions
Chronic Kidney Disease, Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
34
States / cities
Peoria, Arizona • Tempe, Arizona • Los Angeles, California + 31 more
Terminated Not applicable Interventional Results available

Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

NCT01263028
Conditions
Chronic Kidney Disease Stages 3-5
Interventions
Ergocalciferol supplementation
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Beta-Thalassemia
Interventions
arginine butyrate, epoetin alfa
Drug
Lead sponsor
Boston University
Other
Eligibility
3 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Oakland, California • New Haven, Connecticut • Bethesda, Maryland + 2 more
Conditions
Anemia, Traumatic Brain Injury
Interventions
recombinant human erythropoietin, rhEpo, placebo
Drug · Other
Lead sponsor
Claudia Sue Robertson
Other
Eligibility
15 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Conditions
Primary Myelofibrosis, Anemia
Interventions
Luspatercept
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Stanford, California • Jacksonville, Florida + 7 more
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
Interventions
Darbepoetin Alfa, Pegfilgrastim, Paclitaxel, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
6
States / cities
Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts
Conditions
Anaemia
Interventions
Daprodustat (GSK1278863), Placebo, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
49
States / cities
Homewood, Alabama • Little Rock, Arkansas • Downey, California + 44 more
Conditions
Hypoxic-ischemic Encephalopathy
Interventions
erythropoietin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 24 Hours
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Conditions
Cancer
Interventions
Procrit, Placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Azusa, California • Long Beach, California • Lynwood, California + 16 more
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
42
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more
Conditions
Sarcoma
Interventions
Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin, Ifosfamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Erythropoietin on Hematological Adaptations and Physical Performance

NCT05078138
Conditions
Exercise-Induced Anemia, Physical Performance
Interventions
Epoetin Alfa
Drug
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Natick, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Minimally Invasive Biomarker for Asthma Disease Severity

NCT02225678
Conditions
Asthma, Healthy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
End Stage Renal Disease
Interventions
Erythropoietin, Pentoxifylline
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Chicago, Illinois • Kalamazoo, Michigan • Brookhaven, Mississippi + 7 more
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept, Epoetin alfa
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
25
States / cities
Berkeley, California • San Diego, California • Whittier, California + 22 more
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey